1
|
Tong H, Jin Y, Xu Y, Zou B, Ye H, Wu H, Kumar S, Pitman JL, Zhou G, Song Q. Prenatal diagnosis of trisomy 21, 18 and 13 by quantitative pyrosequencing of segmental duplications. Clin Genet 2016; 90:451-455. [PMID: 26948280 DOI: 10.1111/cge.12772] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 03/02/2016] [Accepted: 03/02/2016] [Indexed: 01/22/2023]
Abstract
Chromosomal aberration mostly occurs in chromosomes 21, 18 and 13, with an incidence approximately 1 out of 160 live births in humans, therefore making prenatal diagnosis necessary in clinics. Current methods have drawbacks such as time consuming, high cost, complicated operations and low sensitivity. In this paper, a novel method for rapid and accurate prenatal diagnosis of aneuploidy is proposed based on pyrosequencing, which quantitatively detects the peak height ratio (PHR) of different bases of segmental duplication. A direct polymerase chain reaction (PCR) approach was undertaken, where a small volume of amniotic fluid was used as the starting material without DNA extraction. Single-stranded DNA was prepared from PCR products and subsequently analyzed using pyrosequencing. The PHR between target and reference chromosome of 2.2 for euploid and 3:2 for a trisomy fetus were used as reference. The reference intervals and z scores were calculated for discrimination of aneuploidy. A total of 132 samples were collected, within trisomy 21 (n = 11), trisomy 18 (n = 3), trisomy 13 (n = 2), and unaffected controls (n = 116). A set of six segmental duplications were chosen for analysis. This method had consistent results with karyotyping analysis, a correct diagnosis with 100% sensitivity and 99.9% specificity.
Collapse
Affiliation(s)
- H Tong
- Key Laboratory of Drug Quality Control and Pharmacovigilance of Ministry of Education, China Pharmaceutical University, Nanjing, China
| | - Y Jin
- Key Laboratory of Drug Quality Control and Pharmacovigilance of Ministry of Education, China Pharmaceutical University, Nanjing, China
| | - Y Xu
- Key Laboratory of Drug Quality Control and Pharmacovigilance of Ministry of Education, China Pharmaceutical University, Nanjing, China
| | - B Zou
- Department of pharmacology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
| | - H Ye
- Department of pharmacology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
| | - H Wu
- Department of pharmacology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
| | - S Kumar
- School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
| | - J L Pitman
- School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
| | - G Zhou
- Key Laboratory of Drug Quality Control and Pharmacovigilance of Ministry of Education, China Pharmaceutical University, Nanjing, China. .,Department of pharmacology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
| | - Q Song
- Key Laboratory of Drug Quality Control and Pharmacovigilance of Ministry of Education, China Pharmaceutical University, Nanjing, China. .,Department of pharmacology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
| |
Collapse
|